Breast Cancer Clinical Trial
Official title:
Early Detection and Prediction of Chemotherapy Induced Cardiac Toxicity in Breast Cancer Patients
The goal of this clinical research study is to learn whether different ways of viewing echocardiogram pictures along with blood tests can help to see heart-related side effects of chemotherapy and trastuzumab earlier than the usual tests.
Echocardiogram:
Because of the heart-related side effects of chemotherapy and trastuzumab, your regular
doctor will monitor your heart's function as part of your routine care. You will have
echocardiograms performed before you begin treatment, and then every 3 months. An
echocardiogram uses sound waves to check your heart's health.
If you decide to take part in this study, researchers will take several additional pictures
of your heart during each of your regularly scheduled echocardiograms. The additional
pictures will make the procedure take about 5-10 minutes longer than the regular
echocardiogram. These pictures will be viewed in a different way than the standard
echocardiogram pictures. Researchers hope viewing the pictures this way can help researchers
to find heart problems earlier than the usual tests.
Blood Tests:
Blood (about 4 teaspoon each time) will be drawn during the routine blood draw that occurs
closest to the regularly scheduled echocardiograms.
The heart produces hormones called BNP and NT-proBNP. These hormones can be measured in the
blood. BNP and NT-proBNP levels can be higher when the heart is not working as well.
Researchers will measure these hormones at the time of each echocardiogram. Researchers hope
to learn whether measuring these hormones can help identify the heart-related side effects
of chemotherapy and trastuzumab earlier than the usual tests.
Researchers will also measure metabolic proteins (such as sugars and acids) in the blood.
Researchers hope to learn whether measuring these metabolic proteins can help identify the
heart-related side effects of chemotherapy and trastuzumab earlier than the usual tests.
Because protein, sugar or acid levels may be temporarily changed after you eat, you will be
asked not to eat overnight before having your blood drawn.
Study Visits:
You will have 6 study visits around the time that you have an echocardiogram. These visits
will occur before you take Herceptin, when you begin Herceptin, and 3, 6, 9, and 12 months
later. These study visits will be scheduled on days when you are already making a visit to
your regular doctor. You will not have to make any special visits to the hospital for this
research study.
During each study visit, you will be asked about any symptoms you may be experiencing, and
any medications you may be taking. Your blood pressure and heart rate will be measured.
You will also take a quality of life questionnaire at each study visit. This questionnaire
asks you how the cancer may have interfered with your daily life. It should take about 15
minutes to complete.
Length of Study:
You will be considered off-study once you complete the 6 study visits.
This is an investigational study. Up to 100 patients will take part in this multicenter
study. Up to 20 patients will be enrolled at M. D. Anderson.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A |